Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin

Theranostics

Volumn 7, Issue 11, 2017, Pages 2806-2821

  Kramer, Lovro ^a   Renko, Miha ^a   Završnik, Janja ^a   Turk, Dušan ^a,b   Seeger, Markus A ^c   Vasiljeva, Olga ^a   Grütter, Markus G ^c   Turk, Vito ^a   Turk, Boris ^a,b  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b Center of Excellence CIPKEBIP   (Slovenia)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cathepsin B; Designed ankyrin repeat protein (DARPin); Non invasive diagnostic imaging; Protease; Tumour microenvironment

Indexed keywords

ANKYRIN; CATHEPSIN B; DESIGNED ANKYRIN REPEAT PROTEIN 81; DESIGNED ANKYRIN REPEAT PROTEIN 8H6; UNCLASSIFIED DRUG; CTSB PROTEIN, MOUSE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER MODEL; CELL MEMBRANE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME STRUCTURE; EX VIVO STUDY; FLUORESCENCE IMAGING; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; STROMA CELL; TUMOR DIAGNOSIS; X RAY; ANIMAL; BREAST TUMOR; CHEMISTRY; DIAGNOSTIC IMAGING; DISEASE MODEL; FEMALE; GENETIC PROCEDURES; INTRAVITAL MICROSCOPY; PATHOLOGY; PROCEDURES; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; BREAST NEOPLASMS; CATHEPSIN B; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; FEMALE; INTRAVITAL MICROSCOPY; MICE; MOLECULAR PROBE TECHNIQUES; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 85022342001     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.19081     Document Type: Article

References (67)

1. Deu E, Verdoes M, Bogyo M. New approaches for dissecting protease functions to improve probe development and drug discovery. Nature structural & molecular biology. 2012; 19: 9-16
2. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008; 452: 580-9
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74
4. Sevenich L, Joyce JA. Pericellular proteolysis in cancer. Genes & development. 2014; 28: 2331-47
5. Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nature reviews Cancer. 2015; 15: 712-29
6. Strojnik T, Kos J, Zidanik B, Golouh R, Lah T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clinical cancer research. 1999; 5: 559-67
7. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, et al. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clinical cancer research. 1995; 1: 741-6
8. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes & development. 2011; 25: 2465-79
9. Mohamed MM, Cavallo-Medved D, Rudy D, Anbalagan A, Moin K, Sloane BF. Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cellular physiology and biochemistry. 2010; 25: 315-24
10. Gocheva V, Wang H-W, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes & development. 2010; 24: 241-55
11. Yan D, Wang H-W, Bowman Robert L, Joyce JA. STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1a Activation. Cell Reports. 2016; 16: 2914-27
12. Mikhaylov G, Klimpel D, Schaschke N, Mikac U, Vizovišek M, Fonovic M, et al. Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin B inhibitor. Angewandte Chemie (International ed in English). 2014; 53: 10077-81
13. Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer and Metastasis reviews. 2003; 22: 271-86
14. Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. Journal of nuclear medicine. 2014; 55: 730-5
15. Weissleder R, Tung C-H, Mahmood U, Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnology. 1999; 17: 375-8
16. Watzke A, Kosec G, Kindermann M, Jeske V, Nestler HP, Turk V, et al. Selective activity-based probes for cysteine cathepsins. Angewandte Chemie (International ed in English). 2008; 47: 406-9
17. Hilderbrand SA, Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Current Opinion in Chemical Biology. 2010; 14: 71-9
18. Sanman LE, Bogyo M. Activity-Based Profiling of Proteases. Annual Review of Biochemistry. 2014; 83: 249-73
19. Blum G, Von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nature Chemical Biology. 2007; 3: 668-77
20. Verdoes M, Oresic Bender K, Segal E, van der Linden WA, Syed S, Withana NP, et al. Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. Journal of the American Chemical Society. 2013; 135: 14726-30
21. Hu HY, Vats D, Vizovišek M, Kramer L, Germanier C, Wendt KU, et al. In vivo imaging of mouse tumors by a lipidated cathepsin S substrate. Angewandte Chemie (International ed in English). 2014; 53: 7669-73
22. Nomura DK, Dix MM, Cravatt BF. Activity-based protein profiling for biochemical pathway discovery in cancer. Nature reviews Cancer. 2010; 10: 630-8
23. Li N, Kuo C-L, Paniagua G, van den Elst H, Verdoes M, Willems LI, et al. Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS. Nature Protocols. 2013; 8: 1155-68
24. Ren G, Blum G, Verdoes M, Liu H, Syed S, Edgington LE, et al. Non-Invasive Imaging of Cysteine Cathepsin Activity in Solid Tumors Using a 64Cu-Labeled Activity-Based Probe. PloS one. 2011; 6: e28029
25. Withana NP, Ma X, McGuire HM, Verdoes M, van der Linden WA, Ofori LO, et al. Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes. Scientific Reports. 2016; 6: 19755
26. Caglic D, Globisch A, Kindermann M, Lim N-H, Jeske V, Juretschke H-P, et al. Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation. Bioorganic & medicinal chemistry. 2011; 19: 1055-61
27. Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, Weiskopf K, et al. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chemistry & biology. 2012; 19: 619-28
28. Jaffer FA, Kim D-E, Quinti L, Tung C-H, Aikawa E, Pande AN, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation. 2007; 115: 2292-8
29. Binz HK, Stumpp MT, Forrer P, Amstutz P, Pluckthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. Journal of Molecular Biology. 2003; 332: 489-503
30. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nature Biotechnology. 2004; 22: 575-82
31. Simon M, Zangemeister-Wittke U, Pluckthun A. Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconjugate Chemistry. 2012; 23: 279-86
32. Simon M, Frey R, Zangemeister-Wittke U, Pluckthun A. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconjugate Chemistry. 2013; 24: 1955-66
33. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Research. 2010; 70: 1595-605
34. Seeger MA, Zbinden R, Flutsch A, Gutte PG, Engeler S, Roschitzki-Voser H, et al. Design, construction, and characterization of a second-generation DARP in library with reduced hydrophobicity. Protein science. 2013; 22: 1239-57
35. Schweizer A, Roschitzki-Voser H, Amstutz P, Briand C, Gulotti-Georgieva M, Prenosil E, et al. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure. 2007; 15: 625-36
36. Baici A. The specific velocity plot. A graphical method for determining inhibition parameters for both linear and hyperbolic enzyme inhibitors. European journal of biochemistry. 1981; 119: 9-14
37. Szedlacsek SE, Ostafe V, Serban M, Vlad MO. A re-evaluation of the kinetic equations for hyperbolic tight-binding inhibition. The Biochemical Journal. 1988; 254: 311-2
38. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallographica Section D: Biological Crystallography. 2011; 67: 355-67
39. Turk D. MAIN software for density averaging, model building, structure refinement and validation. Acta Crystallographica Section D: Biological Crystallography. 2013; 69: 1342-57
40. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Research. 2006; 66: 5242-50
41. Weischenfeldt J, Porse B. Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH Protocols. 2008; 2008: pdb.prot5080
42. Hulkower KI, Butler CC, Linebaugh BE, Klaus JL, Keppler D, Giranda VL, et al. Fluorescent microplate assay for cancer cell-associated cathepsin B. European Journal of Biochemistry. 2000; 267: 4165-70
43. Mirkovic B, Markelc B, Butinar M, Mitrovic A, Sosic I, Gobec S, et al. Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity. Oncotarget. 2015; 6: 19027-42
44. Ruettger A, Wiederanders B. Microplate assay for cathepsin detection in viable cells using derivatives of 4-methoxy-beta-naphthylamide. Current Protocols in Protein Science. 2007; Chapter 21: Unit 21
45. Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nature Nanotechnology. 2011; 6: 594-602
46. Kohl A, Binz HK, Forrer P, Stumpp MT, Plückthun A, Grütter MG. Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proceedings of the National Academy of Sciences. 2003; 100: 1700-5
47. Podobnik M, Kuhelj R, Turk V, Turk D. Crystal structure of the wild-type human procathepsin B at 2.5 Å resolution reveals the native active site of a papain-like cysteine protease zymogen. Journal of Molecular Biology. 1997; 271: 774-88
48. Quraishi O, Nagler DK, Fox T, Sivaraman J, Cygler M, Mort JS, et al. The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide. Biochemistry. 1999; 38: 5017-23
49. Bengsch F, Buck A, Gunther SC, Seiz JR, Tacke M, Pfeifer D, et al. Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene. 2014; 33: 4474-84
50. Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Research. 2012; 72: 1199-209
51. Stefan N, Martin-Killias P, Wyss-Stoeckle S, Honegger A, Zangemeister-Wittke U, Plückthun A. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. Journal of Molecular Biology. 2011; 413: 826-43
52. Shuja S, Sheahan K, Murnane MJ. Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. International Journal of Cancer. 1991; 49: 341-6
53. Withana NP, Garland M, Verdoes M, Ofori LO, Segal E, Bogyo M. Labeling of active proteases in fresh-frozen tissues by topical application of quenched activity-based probes. Nature Protocols. 2016; 11: 184-91
54. Yhee JY, Kim SA, Koo H, Son S, Ryu JH, Youn IC, et al. Optical imaging of cancer-related proteases using near-infrared fluorescence matrix metalloproteinase-sensitive and cathepsin B-sensitive probes. Theranostics. 2012; 2: 179-89
55. Ryu JH, Kim SA, Koo H, Yhee JY, Lee A, Na JH, et al. Cathepsin B-sensitive nanoprobe for in vivo tumor diagnosis. Journal of Materials Chemistry. 2011; 21: 17631-4
56. Goldstein R, Sosabowski J, Livanos M, Leyton J, Vigor K, Bhavsar G, et al. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2015; 42: 288-301
57. Münch RC, Muth A, Muik A, Friedel T, Schmatz J, Dreier B, et al. Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nature Communications. 2015; 6: 6246
58. Tamaskovic R, Schwill M, Nagy-Davidescu G, Jost C, Schaefer DC, Verdurmen WP, et al. Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk. Nature Communications. 2016; 7: 11672
59. Kawe M, Forrer P, Amstutz P, Pluckthun A. Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. The Journal of Biological Chemistry. 2006; 281: 40252-63
60. Flütsch A, Schroeder T, Barandun J, Ackermann R, Bühlmann M, Grütter MG. Specific targeting of human caspases using designed ankyrin repeat proteins. Biological Chemistry. 2014; 395: 1243-52
61. Abrahamson M, Mason RW, Hansson H, Buttle DJ, Grubb A, Ohlsson K. Human cystatin C. Role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase. Biochemical Journal. 1991; 273: 621-6
62. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochimica et biophysica acta. 2012; 1824: 68-88
63. Gomez-Auli A, Hillebrand LE, Biniossek ML, Peters C, Reinheckel T, Schilling O. Impact of cathepsin B on the interstitial fluid proteome of murine breast cancers. Biochimie. 2016; 122: 88-98
64. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Research. 1994; 54: 6517-25
65. Rothberg JM, Bailey KM, Wojtkowiak JW, Ben-Nun Y, Bogyo M, Weber E, et al. Acid-Mediated Tumor Proteolysis: Contribution of Cysteine Cathepsins. Neoplasia. 2013; 15: 1125-37
66. Stefan N, Zimmermann M, Simon M, Zangemeister-Wittke U, Pluckthun A. Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting. Bioconjugate Chemistry. 2014; 25: 2144-56
67. Greenbaum D, Medzihradszky KF, Burlingame A, Bogyo M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chemistry & Biology. 2000; 7: 569-81